merger « Science and Enterprise

Heart Disease Biotech Acquired in $13.1B Deal

By Alan, on October 5th, 2020%

A company developing precision medicine drugs to treat inherited heart disorders was acquired by drug maker Bristol Myers Squibb, or BMS, for $13.1 billion. . . . → Read More: Heart Disease Biotech Acquired in $13.1B Deal

Cancer Screening Analytics Company Acquired in $8B Deal

By Alan, on September 21st, 2020%

A company creating a blood test to screen for multiple types of cancer is being acquired by genomics analytics company Illumina for $8 billion in cash and stock. . . . → Read More: Cancer Screening Analytics Company Acquired in $8B Deal

Gilead Acquires Cancer Therapy Biotech for $21B

By Alan, on September 14th, 2020%

Gilead Sciences is acquiring biotechnology company Immunomedics, specializing in immunotherapies for cancer and other diseases, in a deal valued at $21 billion. . . . → Read More: Gilead Acquires Cancer Therapy Biotech for $21B

Food Allergy Biotech Acquired for $2.6B

By Alan, on August 31st, 2020%

Aimmune Therapeutics Inc., a developer of food allergy drugs, was acquired today by global consumer products company Nestlé for $2.6 billion. . . . → Read More: Food Allergy Biotech Acquired for $2.6B

Sanofi Acquires Immune Disease Biotech in $3.7B Deal

By Alan, on August 17th, 2020%

A developer of small-molecule therapies for autoimmune diseases, including multiple sclerosis, and other immune disorders is being acquired by Sanofi. . . . → Read More: Sanofi Acquires Immune Disease Biotech in $3.7B Deal

Infographic – Apple Leads in A.I. Acquistions

By Alan, on July 11th, 2020%

Among the tech giants, Apple is the most aggressive in acquiring start-ups developing A.I. applications over the past 10 years. . . . → Read More: Infographic – Apple Leads in A.I. Acquistions

Merck Inks Three Covid-19 Vaccine, Therapy Deals

By Alan, on May 26th, 2020%

Drug maker Merck today gained a new acquisition, along with collaboration and licensing deals, for vaccines and a therapy for Covid-19 infections. . . . → Read More: Merck Inks Three Covid-19 Vaccine, Therapy Deals

Synthetic Bio Cancer Immunotherapy Company Acquired

By Alan, on December 27th, 2019%

A biotechnology company creating synthetic proteins that invoke the immune system to fight cancer is being acquired by drug maker Astellas Pharma. . . . → Read More: Synthetic Bio Cancer Immunotherapy Company Acquired

Synthetic Bio Company Acquired in $2.35B Deal

By Alan, on December 11th, 2019%

A company developing protein-like therapies for cancer from synthetic bacteria is being acquired by drug maker Sanofi in a deal valued at $2.35 billion. . . . → Read More: Synthetic Bio Company Acquired in $2.35B Deal

Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

By Alan, on September 6th, 2019%

Japanese pharmaceutical company Sumitomo Dainippon agreed to acquire five biotechnology companies and gain an equity stake in the Roivant Sciences group. . . . → Read More: Sumitomo Dainippon, Biotechs in $3B Acquisition Deal

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise